VANCOUVER, B.C., April 18, 2018 /PRNewswire-PRWeb/ -- According to a new series of reports by iData Research, the total
Drug-coated balloons have emerged as a promising technology for treating peripheral arterial disease. Since launching in late 2014, the superficial femoral artery (SFA) DCB market has increased rapidly in market value. In 2017, over 95% of DCBs sold in the U.S. were used in the SFA, with the remainder being used in arteriovenous (AV) access procedures.
However, the market is expected to contract in 2018, following the expiration of the transitional pass-through payment (TPT) on December 31st 2017. As of January 1st 2018, the cost of DCBs has been packaged into payments for associated procedures. As a result, plain-old balloon angioplasty (POBA) and DCB procedures are reimbursed at the same rate.
"The reimbursement cuts will price DCBs above a justifiable range for some hospitals, limiting access to DCB technology and causing unit sales to decline," explains Kamran Zamanian, PhD, CEO at iData Research. "The reduction in reimbursement is also expected to accelerate price erosion in the DCB market. However, annual market declines are anticipated to remain in the low-single digits for the foreseeable future."
Learn More About This 2018 Peripheral Vascular Market Analysis from iData Research
To combat the decline, DCB manufacturers are looking beyond the SFA market to uncover additional growth by developing technologies to address new indications, namely AV access and below-the-knee (BTK).
C. R. Bard is leading the race to obtain approval for and launch a BTK DCB. However, the company is not expected to bring its device to market until 2019. The launch of a BTK DCB in 2019 will provide additional fodder for the total DCB market, contributing to an uptick in unit sales growth.
As of January 2018, Medtronic, C. R. Bard and Philips are the only companies with FDA-approved DCBs. C. R. Bard launched their first DCB product in late 2014, one quarter before Medtronic entered the U.S. market. This early launch date has historically given C. R. Bard the lead in terms of the number of accounts held. However, Medtronic has gained account share since launching and has now pulled even with C. R. Bard.
Many other companies are in the process of bringing a DCB to market, including Boston Scientific, QT Vascular and Surmodics.
For Further Market Information More can be found in a series of reports published by iData Research entitled the U.S. Market Report Suite for Peripheral Vascular Devices and Accessories 2018. The U.S. market for peripheral vascular devices includes peripheral vascular stents, PTA balloon catheters, drug-coated balloons, atherectomy devices, CTO devices, embolic protection devices, peripheral thrombus management, carotid shunts, stent grafts, surgical grafts, diagnostic and interventional catheters and guidewires, introducer sheaths, inferior vena cava filters, AV access thrombectomy devices, vascular closure devices, transcathether embolization devices and peripheral IVUS catheters.
iData's suite of reports on this subject covers the United States and 15 countries in Europe. These include a comprehensive analysis on units sold, market values, average selling prices, procedure volumes, forecasts, as well as detailed competitive market shares and analysis of all major players.
Email us at info(at)idataresearch(dot)net or register online for a U.S. Market Report Suite for Peripheral Vascular Devices 2018 brochure and synopsis.
About iData Research iData Research (http://www.idataresearch.com) is an international consulting and market research firm, dedicated to providing the best in business intelligence for the medical device industry. Our research empowers our clients by providing them with the necessary tools to achieve their goals and do it right the first time.
SOURCE iData Research.
Subscribe to our Free Newsletters!